SCHEMBL4472897

SCHEMBL4472897

CCc1cc(O)c(C)c(C)c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
ACHE P22303 1/20 0.40
TYR P14679 1/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
POLB P06746 2/20 0.37
MAPT P10636 2/20 0.37
THRB P10828 2/20 0.37
KMT2A Q03164 2/20 0.37
HKDC1 Q2TB90 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MCL1 Q07820 2/20 0.37
APEX1 P27695 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31092530 0.83 GABRA1 (0.42) ALOX15ALOX12GABRA1GABRB2TYR
SCHEMBL19927818 0.83 GABRA1 (0.42) ALOX15ALOX12GABRA1GABRB2TYR
SCHEMBL5676818 0.81 ALOX15 (0.43) ALOX15ALOX12GABRA1GABRB2ACHE
SCHEMBL31092533 0.81 GABRA1 (0.41) ALOX15ALOX12GABRA1GABRB2TYR
SCHEMBL19765532 0.81 ALOX15 (0.43) ALOX15ALOX12GABRA1GABRB2ACHE
SCHEMBL24672233 0.81 GABRA1 (0.41) ALOX15ALOX12GABRA1GABRB2TYR
SCHEMBL16900551 0.80 ALOX15 (0.39) ALOX15ALOX12GABRA1GABRB2ACHE
Methane SCHEMBL27819860 0.79 SHBG (0.45) ACHETYRKDM4EALDH1A1MEN1
Methane SCHEMBL2221487 0.79 SHBG (0.45) ACHETYRKDM4EALDH1A1MEN1
SCHEMBL4969048 0.79 TYR (0.53) ALOX15TYRKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 ALOX15 3/4885ALOX12 4/4885GABRA1 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.